Otsuka Pharmaceutical Co., Ltd.
Tokyo, Japan
NCT Number: NCT03179787
The purpose of this study is to evaluate the safety and effectiveness of aripiprazole in patients with autism in the real world clinical setting in Japan.
Looking for future studies?
Notify Me6 year–17 year
All sexes
Observational
Tokyo, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
oral administration of aripiprazole
Time frame: Baseline, Week 4, 8, 16, 24, 52
Using caregiver-rated ABC-J, the degree of aberrant behaviors was scored on four levels ranging from 0 'not at all a problem', 1 'slight problem', 2 'moderately serious problem' to 3 'the problem is severe in degree' in irritability subscale (including 15 items describing symptoms of irritability, such as temper tantrums, aggression, mood changes, and self-injury).
The irritability subscale score ranging from 0 to 45 was derived from the sum of the 15 items and higher values represent a worse outcome.
Otsuka Pharmaceutical Co., Ltd.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05910658
Autism, Autism Spectrum Disorder
Brookline, Massachusetts, United States
View Trial DetailsNCT06216613
Autism, Autism Spectrum Disorder
Kansas City, Kansas, United States
View Trial DetailsNCT05176808
Active Autistic Disorder, Asperger Syndrome
Baltimore, Maryland, United States
View Trial DetailsNCT06685822
Autism, Autism Spectrum Disorder
Eldoret, Kenya
View Trial Details